NEW YORK (GenomeWeb) – Leerink Partners and Canaccord Genuity today initiated coverage of HTG Molecular Diagnostics. Leerink gave the firm's shares an "Outperform" rating and an $18 price target while Canaccord gave them a "Buy" rating with a $17 price target.

Canaccord analyst Mark Massaro said in a report that HTG has the opportunity to be a leading player in the approximately $27 billion molecular profiling market, especially for oncology, which he estimated was more than $15 billion.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.

Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.

In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.